Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Curis, Inc. (CRIS) Stock Down -16.96% Today?

Why Is Curis, Inc. (CRIS) Stock Down -16.96% Today?

Key Takeaways

  • CRIS shares fell 16.96% to $0.5101, down from the prior close of $0.6143, as sellers took profits after a two-session rally of roughly 41%.
  • No new company-specific announcement, filing, or analyst action accompanied Thursday's decline; the reversal followed Wednesday's shareholder vote approving a reverse stock split.
  • Secondary pressure came from the unresolved Nasdaq listing issue — a November 2 delisting determination remains under appeal, and the company has said there is no assurance it will stay listed.
  • Curis is a pre-revenue, single-asset clinical-stage biotech with a cash runway guided only into the first quarter of 2027.
  • The broader tape and small-cap biotech were not the driver; the move was stock-specific in a thinly traded, low-float name.
  • Volume was running below the heavy turnover of the prior two sessions, consistent with thinning demand into the rebound.
  • News Significance Score: 22/100 — procedural reverse-split news only, with a decline roughly twice the stock's typical daily swing.
  • Traders are watching whether the bid stabilizes above the $0.44–$0.45 area and awaiting initial TakeAim CLL data expected by year-end.
  • For deeper research, explore Price Targets, Earnings, and Forecast pages dedicated to the ticker.
  • Track the strongest automated strategies in current conditions on Trending AI Robots.

Opening Summary

Curis, Inc. (CRIS) is a Lexington, Massachusetts-based clinical-stage biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor being tested in combination with BTK inhibitors in primary central nervous system lymphoma (PCNSL) and chronic lymphocytic leukemia (CLL). The stock traded at $0.5101 in Thursday's session, a decline of 16.96% from the previous close of $0.6143. The direction was unambiguously negative, and it erased a meaningful slice of the two-day advance that had lifted shares from $0.4358 on Monday to $0.6143 on Wednesday. No fresh press release, SEC filing, or analyst action explained the pullback; the move is best read as profit-taking in a low-float micro-cap after a sharp, news-driven run.

Profit-Taking After a Two-Session Surge

Wednesday's gain of 13.38% came on more than 1.5 million shares and followed Tuesday's 24.32% jump — a combined advance of about 41% in two sessions, during which the stock briefly traded above the $1.00 threshold in pre-market activity. Moves of that scale in a name with a float of only a few million shares typically attract short-horizon momentum capital, and that capital is quick to exit.

Thursday's tape fits that pattern rather than a fundamental reassessment: the decline began in the opening half hour and accelerated through the morning, with no disclosure to match. When a rally is built on positioning and anticipation rather than a change in intrinsic value, the unwind frequently retraces a large portion of the advance without a catalyst of its own.

Reverse Split Approved; Listing Overhang Persists

At a virtual special meeting on November 18, stockholders approved amendments authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-12, with the board choosing the final ratio and timing within six months. The company has framed the step as necessary to lift the share price above Nasdaq's $1.00 minimum bid requirement.

That approval is a compliance mechanism, not an improvement in the business. It follows a November 2 staff determination that the bid price had closed below $1.00 for 30 consecutive business days, a finding made more severe because Curis completed a 1-for-20 reverse split on July 6, 2026 and was therefore ineligible for a standard cure period. The company remains under a one-year discretionary panel monitor imposed after a July 24 hearing decision and has said it intends to request a new hearing, while cautioning that there is no assurance the appeal succeeds or that shares stay listed. For investors, a confirmed split plus an unresolved delisting question is a reason to reduce exposure into strength, not add to it.

Cash Runway and the December Readout

Third-quarter results, reported November 12, showed no revenue, a net loss of $8.1 million, and cash and equivalents of $5.0 million at September 30. Together with roughly $7.5 million in net proceeds from an October private placement, management projects funding into the first quarter of 2027 — a runway that leaves little margin for error. The operating thesis rests almost entirely on emavusertib: management disclosed 12 patients enrolled across 11 sites in the TakeAim CLL study, with initial data expected by the end of 2026, and full PCNSL enrollment targeted by the end of 2027. An analyst price target was cut sharply on November 13 following the share-count increase from the placement, a reminder that dilution remains a live constraint on valuation.

Market Context and Trading Activity

Roughly 300,000 shares had changed hands by midday, a pace well below the elevated turnover of the prior two sessions and broadly in line with the stock's recent baseline, indicating that the selling was not accompanied by a fresh institutional event. The move was idiosyncratic: broader equity indices and small-cap biotech benchmarks did not decline in comparable fashion, so sector sympathy does not explain the magnitude.

Technically, the pullback stalled near $0.5060, an area that had acted as resistance in mid-November before the breakout, and the price slipped back below its short-term moving averages after briefly reclaiming them. The stock remains roughly 96% lower year-to-date and far below its 200-day trend, so the rally was a countertrend bounce rather than a trend reversal.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Curis earns 22 out of 100. The verified news was procedural: shareholder approval of a reverse split designed to address a Nasdaq bid-price deficiency, material to listing status but not to the company's underlying value, and published before today's session. The decline was roughly 2.4 times the stock's average absolute daily move of about 7% over the past 60 sessions, but moves of that size or larger occurred seven times in that stretch. Modest news and a familiar-sized swing combine into a low score.

What Comes Next for CRIS

The central scheduled event is initial TakeAim CLL data, expected before year-end; the readout will be judged on signs of clinical activity in combination with zanubrutinib, and a disappointing result would carry outsized weight given the single-asset model. Management must also announce the reverse split ratio and effective date, file final vote results, and pursue its Nasdaq hearing. Investors should watch cash consumption against the first-quarter 2027 runway, any further warrant exercises or resale registration activity that could add supply, and commentary on PCNSL enrollment. Risks include continued dilution, potential delisting, thin liquidity that amplifies both directions, and binary clinical outcomes.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics, and traded symbols, so the lineup rotates as market conditions shift. Reviewing the current leaders can help traders compare disciplined, rules-based approaches against their own process — explore the page to see which automated strategies are working right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CRIS

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


Aroon Indicator for CRIS shows an upward move is likely

CRIS's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 70 similar instances where the Aroon Indicator showed a similar pattern. In 64 of the 70 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +40.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRIS advanced for three days, in 137 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The 10-day RSI Indicator for CRIS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 13 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRIS as a result. In 70 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

CRIS moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CRIS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CRIS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.468) is normal, around the industry mean (3.596). P/E Ratio (0.248) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (3.280) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a drug company

Industry Biotechnology

Industry
Biotechnology
Address
128 Spring Street
Phone
+1 617 503-6500
Employees
24
Web
https://www.curis.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.